in a physician’s office to reveal glucose patterns and potential problems, including hyperglycemic and hypoglycemic episodes. The data leads to more informed treatment decisions. Connected Care: The company offers connected care solutions, including the MiniMed Connect, a system providing remote access to pump and sensor data on the user's smartphone. CareLink Therapy Management Software: The company’s Web-based therapy management software solutions, including CareLink Personal software for patients and CareLink Pro software for healthcare professionals, to help patients and their health care providers control their diabetes. Customers: The primary medical specialists who use and/or prescribe its Diabetes products are endocrinologists, diabetologists, and internists. Competition: The company’s primary competitors are Johnson & Johnson; DexCom, Inc.; Tandem Diabetes Care Inc.; Insulet Corporation; and F. Hoffmann-La Roche Ltd. Acquisitions On January 26, 2015, pursuant to a transaction agreement, dated as of June 15, 2014 (the Transaction Agreement), Medtronic, Inc. and Covidien became subsidiaries of the company. On October 2, 2015, the company's Coronary & Structural Heart division acquired Twelve, Inc. (Twelve), a privately-held medical device company that focuses on the development of a transcatheter mitral valve replacement device. On August 11, 2015, the company's Surgical Solutions division acquired RF Surgical Systems, Inc. (RF Surgical), a medical device company that focuses on the detection and prevention of retained surgical sponges. On August 31, 2015, the company's Neurovascular division acquired Medina Medical (Medina), a privately-held medical device company that focuses on commercializing treatments for vascular abnormalities of the brain, including cerebral aneurysms. Sales and Marketing The company sells most of its medical devices and therapies through direct sales representatives in the U.S. and a combination of direct sales representatives and independent distributors in markets outside the U.S. Strategy The company’s strategy includes the following: delivering a strong launch cadence of meaningful therapies and procedures; addressing the inequity in health care access globally, primarily in emerging markets; and becoming a leader in value-based health care. Seasonality The number of medical procedures incorporating the company’s products is generally lower during summer months, due to summer vacation schedules in the northern hemisphere, particularly in European countries. Research and Development During the year 2016, the company spent $2.2 billion on research and development. Regulations The company’s products are subject to regulation by government agencies, including the U.S. FDA and similar agencies outside the U.S. Under Section 13(r) of the Exchange Act, the company is required to include certain disclosures in its periodic reports if the company or any of its affiliates knowingly engaged in certain specified activities during the period covered by the report. History Medtronic plc was founded in 1949. The company was incorporated as a Minnesota corporation in 1957.
(MDT:New York Consolidated)
20 On Hatch
Lower Hatch Street
Phone: 353 1 438 1700
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for MDT.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MEDTRONIC PLC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.